QLS5133

QLS5133 is a novel **antibody-drug conjugate (ADC)** developed primarily for the treatment of advanced solid tumors. It consists of a monoclonal antibody targeting **cadherin-6 (CDH6)**, a cell surface antigen overexpressed in certain cancers, linked to a cytotoxic payload—specifically, a **DNA topoisomerase I inhibitor**. The antibody delivers the cytotoxic drug specifically to tumor cells via binding to CDH6, after which the conjugate is internalized and the cytotoxic payload is released inside the cell, leading to targeted tumor cell death. The mechanism also allows for a bystander effect, potentially impacting neighboring tumor cells. QLS5133 is being investigated as monotherapy in a multi-stage, phase 1/2 clinical trial enrolling patients with advanced solid tumors who have limited treatment options. The drug is notable for its dual targeting and cytotoxic approach, aiming to address resistance to existing therapies. The developer and sponsor is **Qilu Pharmaceutical**[1][2][3][5][7][9].

Brand names

QLS5133QLS-5133QLS 5133

Other names

QLS5133QLS-5133QLS 5133